NCT05312372 2026-02-17
S095033 in Combination With Paclitaxel as 2nd- or 3rd-line Treatment in Participants With Advanced or Metastatic ESCC
Servier
Phase 1/2 Withdrawn
Clinical Trials
13 trialsNCT06420908 2025-08-26
Adebrelimab Combined With Chemoradiotherapy for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma (ESCC)
Hebei Medical University Fourth Hospital
Phase NA Withdrawn
NCT06702384 2025-02-06
MAGnET
Royal Marsden NHS Foundation Trust
Withdrawn
NCT04625543 2022-04-26
Neoadjuvant Immunotherapy to ESCC
Qilu Hospital of Shandong University
Phase 2 Withdrawn
NCT03592407 2022-03-08
Epacadostat and Pembrolizumab Before Surgery in Treating Participants With Stage II-III Esophageal or Gastroesophageal Cancer
City of Hope Medical Center
Phase 2 Withdrawn
NCT02272699 2021-03-18
Neoadjuvant Treatment of Nimotuzumab With Chemotherapy or Radiotherapy in Resectable Esophageal Squamous Cell Carcinoma
Peking University
Phase 2/3 Withdrawn
NCT01498757 2019-05-21
Genome-wide Association Study
Samsung Medical Center
Withdrawn
NCT00372450 2019-03-20
Plastic Stents Compared With Metal Stents in Treating Patients With Malignant Dysphagia Caused by Esophageal Cancer or Gastroesophageal Junction Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase NA Withdrawn
NCT03307941 2017-12-19
ARTEMIS-Eso
Jules Bordet Institute
Phase 1/2 Withdrawn
NCT02033538 2015-03-05
Neoadjuvant Chemotherapy of Nanoparticle Albumin-bound Paclitaxel in Squamous Cell Carcinoma of Esophagus
Zhejiang University
Phase 2 Withdrawn
NCT02034968 2015-03-05
Nimotuzumab Plus Nab-paclitaxel and Cisplatin in Treating Patients With Advanced Esophageal Carcinoma
Zhejiang University
Phase 2 Withdrawn
NCT02041819 2015-03-05
Neoadjuvant Chemotherapy of Nimotuzumab Plus Nab-Paclitaxel in Squamous Cell Carcinoma of Esophagus
Zhejiang University
Phase 2 Withdrawn
NCT02011594 2015-02-12
Phase II Study of Maintenance Treatment of Nimotuzumab for Advanced Esophageal Carcinoma
Zhejiang University
Phase 2 Withdrawn